AP NEWS
ADVERTISEMENT
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Cyclerion to Participate in the 39th Annual J.P. Morgan Healthcare Conference and H.C. ...

January 4, 2021 GMT

CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing innovative medicines for people with serious diseases of the central nervous system (CNS), today announced that it will present a corporate overview at upcoming investor conferences:

  • 39th Annual J.P. Morgan Healthcare Conference. A presentation and Q&A discussion will take place on Thursday, January 14, 2021 at 3:40 p.m. ET and a live webcast may be accessed within the Investors & Media section of the  Cyclerion.com  website. An archived replay will be available for approximately 90 days following the presentation.
  • H.C. Wainwright BioConnect Conference. An on-demand presentation will be available on Monday January 11, 2021 at 6:00 a.m. ET at the conference website.

ADVERTISEMENT

About Cyclerion Therapeutics 
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing innovative medicines for people with serious diseases of the central nervous system (CNS). Cyclerion’s lead program is CY6463 a pioneering CNS-penetrant sGC stimulator in clinical development for Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) and Alzheimer’s Disease with Vascular pathology (ADv).

For more information about Cyclerion, please visit  https://www.cyclerion.com/  and follow us on Twitter (@Cyclerion) and LinkedIn ( www.linkedin.com/company/cyclerion ).

Investors
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com